|
1
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD, et al: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Coiffier B: Rituximab in the treatment of
diffuse large B-cell lymphomas. Semin Oncol. 29:30–35.
2002.PubMed/NCBI
|
|
3
|
Habermann TM, Weller EA, Morrison VA,
Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI,
Peterson BA, et al: Rituximab-CHOP versus CHOP alone or with
maintenance rituximab in older patients with diffuse large B-cell
lymphoma. J Clin Oncol. 24:3121–3127. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sehn LH, Donaldson J, Chhanabhai M,
Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli
JJ, Sutherland J, et al: Introduction of combined CHOP plus
rituximab therapy dramatically improved outcome of diffuse large
B-cell lymphoma in British Columbia. J Clin Oncol. 23:5027–5033.
2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Park JJ, Beckman-Harned S, Cho G, Kim D
and Kim H: The current acceptance, accessibility and recognition of
Chinese and Ayurvedic medicine in the United States in the public,
governmental, and industrial sectors. Chin J Integr Med.
18:405–408. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rashrash M, Schommer JC and Brown LM:
Prevalence and Predictors of Herbal Medicine Use Among Adults in
the United States. J Patient Exp. 4:108–113. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Scheid V, Tuffrey V, Weijburg T, Bovey M
and Ward T: Chinese medicine treatment for menopausal symptoms in
the UK health service: Is a clinical trial warranted? Maturitas.
80:179–186. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhai L, Chen C, Zhao Y and Lin L: Effect
of Qi-benefiting and Phlegm-eliminating Recipe on Proliferation and
Serine/threonine-protein Kinase AKT Expression of Diffused Large
B-cell Lymphoma Cells. J Guangzhou Univ Tradit Chin Med.
33:556–560. 2016.(In Chinese).
|
|
9
|
Gao T, Chen Z and Zhang E: Theoretical
Basis and Evidence-based Basis of Invigorating Qi and Expelling
Phlegm Method in Preventing and Treating Lung Cancer. Liaoning J
Tradit Chin Med. 45:43–46. 2018.(In Chinese).
|
|
10
|
Kim K, Zakharkin SO and Allison DB:
Expectations, validity, and reality in gene expression profiling. J
Clin Epidemiol. 63:950–959. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Craig VJ, Cogliatti SB, Imig J, Renner C,
Neuenschwander S, Rehrauer H, Schlapbach R, Dirnhofer S, Tzankov A
and Müller A: Myc-mediated repression of microRNA-34a promotes
high-grade transformation of B-cell lymphoma by dysregulation of
FoxP1. Blood. 117:6227–6236. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215.
2011.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Tang Y, Tang Y and Cheng YS: miR-34a
inhibits pancreatic cancer progression through Snail1-mediated
epithelial-mesenchymal transition and the Notch signaling pathway.
Sci Rep. 7:38232:2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lodygin D, Tarasov V, Epanchintsev A,
Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking
H: Inactivation of miR-34a by aberrant CpG methylation in multiple
types of cancer. Cell Cycle. 7:2591–2600. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Krzeszinski JY, Wei W, Huynh H, Jin Z,
Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, et
al: miR-34a blocks osteoporosis and bone metastasis by inhibiting
osteoclastogenesis and Tgif2. Nature. 512:431–435. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chim CS, Wong KY, Qi Y, Loong F, Lam WL,
Wong LG, Jin DY, Costello JF and Liang R: Epigenetic inactivation
of the miR-34a in hematological malignancies. Carcinogenesis.
31:745–750. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Christoffersen NR, Shalgi R, Frankel LB,
Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M and Lund
AH: p53-independent upregulation of miR-34a during oncogene-induced
senescence represses MYC. Cell Death Differ. 17:236–245.
2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jia L, Chopp M, Wang L, Lu X, Zhang Y,
Szalad A and Zhang ZG: miR-34a Regulates Axonal Growth of Dorsal
Root Ganglia Neurons by Targeting FOXP2 and VAT1 in Postnatal and
Adult Mouse. Mol Neurobiol. 55:9089–9099. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Rao DS, O'Connell RM, Chaudhuri AA,
Garcia-Flores Y, Geiger TL and Baltimore D: MicroRNA-34a perturbs B
lymphocyte development by repressing the forkhead box transcription
factor Foxp1. Immunity. 33:48–59. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res. 45 D:D353–D361.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yamada O and Kawauchi K: The role of the
JAK-STAT pathway and related signal cascades in telomerase
activation during the development of hematologic malignancies.
JAK-STAT. 2(e25256)2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dietrich DR: Toxicological and
pathological applications of proliferating cell nuclear antigen
(PCNA), a novel endogenous marker for cell proliferation. Crit Rev
Toxicol. 23:77–109. 1993.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Steelman LS, Pohnert SC, Shelton JG,
Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT, Raf/MEK/ERK,
PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.
Leukemia. 18:189–218. 2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gupta A, Shah K, Oza MJ and Behl T:
Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for
cancer treatment. Biomed Pharmacother. 109:484–492. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Song W, Liu MG, Zhang JB, Zhang JJ, Sun MM
and Yu QK: Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in
non-Hodgkin's lymphoma. Eur Rev Med Pharmacol Sci. 20:1093–1097.
2016.PubMed/NCBI
|
|
29
|
Letellier E and Haan S: SOCS2:
Physiological and pathological functions. Front Biosci (Elite Ed).
8:189–204. 2016.PubMed/NCBI
|
|
30
|
Michlewski G and Cáceres JF:
Post-transcriptional control of miRNA biogenesis. RNA. 25:1–16.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Marques SC, Ranjbar B, Laursen MB,
Falgreen S, Bilgrau AE, Bødker JS, Jørgensen LK, Primo MN, Schmitz
A, Ettrup MS, et al: High miR-34a expression improves response to
doxorubicin in diffuse large B-cell lymphoma. Exp Hematol.
44:238–246 e232. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
He M, Gao L, Zhang S, Tao L, Wang J, Yang
J and Zhu M: Prognostic significance of miR-34a and its target
proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and
DLBCL. Gastric Cancer. 17:431–441. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Saleh LM, Wang W, Herman SE, Saba NS,
Anastas V, Barber E, Corrigan-Cummins M, Farooqui M, Sun C, Sarasua
SM, et al: Ibrutinib downregulates a subset of miRNA leading to
upregulation of tumor suppressors and inhibition of cell
proliferation in chronic lymphocytic leukemia. Leukemia.
31:340–349. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Musilova K and Mraz M: MicroRNAs in B-cell
lymphomas: How a complex biology gets more complex. Leukemia.
29:1004–1017. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xiao J, He B, Zou Y, Chen X, Lu X, Xie M,
Li W, He S, You S and Chen Q: Prognostic value of decreased FOXP1
protein expression in various tumors: A systematic review and
meta-analysis. Sci Rep. 6(30437)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Flori M, Schmid CA, Sumrall ET, Tzankov A,
Law CW, Robinson MD and Müller A: The hematopoietic oncoprotein
FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma
by repressing S1PR2 signaling. Blood. 127:1438–1448.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gascoyne DM and Banham AH: The
significance of FOXP1 in diffuse large B-cell lymphoma. Leuk
Lymphoma. 58:1037–1051. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pfeifer M, Grau M, Lenze D, Wenzel SS,
Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, et
al: PTEN loss defines a PI3K/AKT pathway-dependent germinal center
subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA.
110:12420–12425. 2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Li Z and Rana TM: Therapeutic targeting of
microRNAs: Current status and future challenges. Nat Rev Drug
Discov. 13:622–638. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Craig VJ, Tzankov A, Flori M, Schmid CA,
Bader AG and Müller A: Systemic microRNA-34a delivery induces
apoptosis and abrogates growth of diffuse large B-cell lymphoma in
vivo. Leukemia. 26:2421–2424. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Di Martino MT, Leone E, Amodio N, Foresta
U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli
E, et al: Synthetic miR-34a mimics as a novel therapeutic agent for
multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res.
18:6260–6270. 2012.PubMed/NCBI View Article : Google Scholar
|
